Compugen (CGEN) Accumulated Expenses (2009 - 2026)

Compugen (CGEN) posted quarterly Accumulated Expenses of $4.0 million for Q1 2026, down 28.98% on a QoQ basis from $5.7 million in Q4 2025.

Compugen (CGEN) Accumulated Expenses (2009 - 2026) Analysis & Trends

Compugen has reported Accumulated Expenses for 18 years, with the latest figure at $4.0 million in Q1 2026.

Accumulated Expenses for Q1 2026 came in at $4.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $4.0 million (changed N/A YoY), and the FY2025 annual result was $5.7 million, up 9.83% from the prior year.
Accumulated Expenses declined to $4.0 million in Q1 2026, from $5.7 million in the prior quarter.
Over five years, Accumulated Expenses peaked at $9.2 million in Q4 2022 and troughed at $2.5 million in Q2 2024.
A 5-year average of $6.2 million and a median of $5.7 million in 2025 frame the typical range for Accumulated Expenses.
The widest annual swing landed in 2024, when Accumulated Expenses tumbled 70.96%; it then surged 99.43% in 2025.
A 5-year view of Accumulated Expenses shows it stood at $9.2 million in 2022, then declined by 14.66% to $7.9 million in 2023, then plunged by 34.23% to $5.2 million in 2024, then rose by 9.83% to $5.7 million in 2025, then dropped by 28.98% to $4.0 million in 2026.
Per Business Quant data, the three most recent Accumulated Expenses figures were $4.0 million in Q1 2026, $5.7 million in Q4 2025, and $4.9 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Compugen	227.88 Mn	136.13 Mn	352,000.00

Download Data